Impact of Biannual Mass Azithromycin Treatment on Enteropathogen Carriage in Children &lt;5 Years Old in Niger | Zendy

James A Platts-Mills | Zendy; Elias G Ayoub | Zendy; Jixian Zhang | Zendy; Elizabeth T. Rogawski McQuade | Zendy; Ahmed M. Arzika | Zendy; Ramatou Maliki | Zendy; Amza Abdou | Zendy; Jeremy D. Keenan | Zendy; Thomas M. Lietman | Zendy; Jie Liu | Zendy; Eric R. Houpt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Biannual Mass Azithromycin Treatment on Enteropathogen Carriage in Children <5 Years Old in Niger

Author(s) -

James A Platts-Mills,

Elias G Ayoub,

Jixian Zhang,

Elizabeth T. Rogawski McQuade,

Ahmed M. Arzika,

Ramatou Maliki,

Amza Abdou,

Jeremy D. Keenan,

Thomas M. Lietman,

Jie Liu,

Eric R. Houpt

Publication year - 2022

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab1046

Subject(s) - azithromycin , medicine , carriage , confidence interval , randomized controlled trial , microbiology and biotechnology , antibiotics , biology , pathology

We analyzed samples obtained at baseline and 24 months in a mass azithromycin administration trial in Niger using quantitative polymerase chain reaction. In villages randomized to azithromycin, Shigella was the only pathogen reduced at 24 months (prevalence ratio, 0.36 [95% confidence interval: .17–.79]; difference in log quantity, −.42 [−.75 to −.10]).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research